A short set of practical guides on how to prioritize accounts, which buying signals actually matter in biotech and pharma, how to sell around industry conferences, how to build an ICP as a CRO or CDMO, and when to time outreach around readiness signals.
A working calendar of the major US life science conferences that matter for go-to-market: what each show is, who attends, therapeutic and functional focus, typical timing, and the outreach window it opens.
How Arcova stacks up against ZoomInfo, Apollo, Clay, SciLeads, Vendelux, and outreach platforms life science teams already use.
Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.
A practical account prioritization framework for life science sales teams: gate on fit first, then use buying-readiness signals to decide when to act inside your best-fit list.
A working framework for life science buying signals: which events point to new budget or new work to outsource (funding, clinical and regulatory milestones, hiring, expansion), and which fill in the picture around them.
How to turn exhibitor, speaker, and attendee presence at BIO, ASCO, ASH, SITC, ESMO and other life science conferences into timed outreach, not a badge scan you follow up on weeks later.
How to build an ideal customer profile for a CRO, CDMO, or life science tools and services company: the two-layer model (company fit and buyer fit) that generic B2B ICP templates miss.
When to reach out to a life science account, not just who to target: the readiness dimensions behind a buying signal, how quickly they should be acted on, and why they decay at different rates.
What CMC, clinical operations, regulatory, and executive hiring actually tells a life science seller, the job each hiring signal does, and how fast the window closes.
Trial registrations, phase transitions, site expansions, sponsor changes, and investigator activity are dated public evidence of the operational work a life science program just took on. Here is how to read that and reach the account before your competitors do.
FDA approvals, Fast Track, Breakthrough Therapy, Priority Review, and Orphan Drug designations are dated public evidence of where a life science program stands with the regulator and where it is heading. Here is how to read each one and reach the account before your competitors do.
Funding rounds, grants, IPOs, milestone payments, and licensing deals are dated proof that a life science company's spending capacity just changed. Here is how to read where that money is heading and reach the account before your competitors do.
What exhibiting, presenting, and attending a conference each tell a life science seller, the job each signal does in timing a conversation, and why the outreach window closes quickly after a show.
Publications and patents are the clearest public record of what a life science company is researching and where its science is heading. Here is how to read that direction and reach an account before your competitors see the shift.
How life science sellers can interpret leadership appointments, promotions, departures, and contact moves without mistaking people changes for buying intent.
How life science sales teams can choose weekly or monthly signal review based on account priority, decision timing, source quality, and team capacity.
A careful guide to when CRO and CDMO needs may form, what public milestones can and cannot show, and why procurement timing must be verified account by account.
How to investigate a possible biotech manufacturing need using program, CMC, financing, regulatory, and facility evidence without treating signals as proof.
A role-based map for researching CRO, CDMO, and instrument buying teams without assuming one title, one approver, or the same process at every biotech.
Research biotech instrument timing through funding, grants, facility changes, scientific hiring, and program milestones without assuming a purchase.
A persona-filtered CRO and CDMO conference guide: clinical, sourcing, manufacturing, partnering, and niche shows to consider for BD.
Public medtech and diagnostics buying signals: FDA clearances and approvals, coverage decisions, funding, hiring, partnerships, and expansion.
A step-by-step guide to running email and LinkedIn outreach together for life science sales: building the list, structuring a 3-week sequence, handing it to your sending tool, and measuring it.
A step-by-step method for scoring company and buyer fit in life science sales: define the ICP layers, pick criteria you can actually check, score and band accounts, and act on each band.
A step-by-step method for scoring buying readiness in life science sales: group signals by what changed, weight each signal by the question it answers, let signals fade with age, and combine the result with fit into an action.
The operational playbook for timing outreach off buying signals: how often to check for new signals, how fast to respond by signal type, recency windows, and what to say versus leave out.
Sending a follow-up email is the easy part. Here is how to turn the conversations you had at a conference into meetings and real pipeline.
A step-by-step method for turning one great existing customer into a target account list: pick the right anchor, derive what makes them a fit, turn it into criteria, and find and validate look-alikes.
A defensible method for finding biotechs preparing Phase 2 or Phase 3 studies by combining registry phase fields, dates, sponsor updates, and fit.
Use a PDUFA target action date to plan FDA-review outreach without assuming approval or treating the date as a guaranteed FDA action.
An on-site field guide for life science BD reps: route the venue, protect meetings, use sessions as account research, and run team handoffs.
A practical go-to-market playbook for contract research organizations: how a CRO buyer profile differs from a generic life science ICP, which readiness signals matter most, conference strategy, and outreach cadence.
A practical go-to-market playbook for CDMOs: how modality and manufacturing scope reshape the ICP, which readiness signals actually predict a capacity or tech-transfer need, conference strategy, and outreach cadence.
A practical go-to-market playbook for life science tools, instruments, software, and research services vendors: how the ICP differs from a clinical-stage playbook, which signals matter most, conference strategy, and cadence.
A working comparison of HeyReach, Lemlist, Instantly, Smartlead, Outreach, and Salesloft for life science GTM teams, plus where a signal-grounded sequence layer like Arcova fits upstream of all of them.
A working comparison of ZoomInfo, Apollo, SciLeads, Cognism, and Clay for life science GTM teams, plus how a life science-specific fit and readiness lens like Arcova sits on top of whichever one you use.
A working comparison of Bombora, ZoomInfo Intent, and Clay for life science GTM teams, and why generic web-intent topics miss the clinical, regulatory, and funding events that actually predict readiness.
A working look at Vendelux and the realistic alternative most life science teams actually run: manually checking exhibitor and attendee pages on each show's own site, quarter after quarter.
A working comparison of Clay, Bettercontact, and the broader enrichment-waterfall category, and why a life science team usually needs a scoring layer behind the CRM, not another general enrichment tool.
Plain-language definitions of the fit, readiness, and buying-signal terms used in life science sales: from fit score and ICP to phase transitions, FDA milestones, and conference signals.
Plain-language definitions of the core go-to-market terms and life science specific terms sellers need: ICP, TAM/SAM/SOM, fit score, readiness, CRO, CDMO, CGT, clinical trial phases, IND/NDA/BLA, and more.
Readiness scoring is the practice of rating how likely an account or contact is to be in an active buying window right now, based on recent public buying signals rather than static firmographics. Definition, method, and how it differs from a fit score.
Signal-based GTM for life science targets and times outreach using public, industry-specific buying signals such as funding, hiring, clinical trial milestones, regulatory events, and publications, rather than static firmographics or generic intent data.
A clear comparison of contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and contract manufacturing organizations (CMOs): what each does, and how they differ by scope of service, not size.
A clear comparison of the three core FDA application types in drug development: the IND (before human trials, any modality), the NDA (marketing approval for small molecules), and the BLA (marketing approval for biologics).